Get started
Author

Weixiu Luo

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
2014 · Olivia Pagani, Meredith M. Regan, et al. · New England Journal of Medicine · 751
PDF
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014 · Joyce F Liu, William T Barry, et al. · The Lancet Oncology · 585
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
2019 · Panagiotis A Konstantinopoulos, William T Barry, et al. · The Lancet Oncology · 262
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
2019 · Panagiotis A. Konstantinopoulos, Weixiu Luo, et al. · Journal of Clinical Oncology · 226
PDF
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
2019 · Joyce F. Liu, Christina Herold, et al. · JAMA Oncology · 225
PDF
Variability Among Breast Radiation Oncologists in Delineation of the Postsurgical Lumpectomy Cavity
2007 · Daniel M. Landis, Weixiu Luo, et al. · International Journal of Radiation Oncology*Biology*Physics · 213
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
2015 · Jürg Bernhard, Weixiu Luo, et al. · The Lancet Oncology · 178
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
2017 · Poornima Saha, Meredith M. Regan, et al. · Journal of Clinical Oncology · 151
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
2016 · Karin Ribi, Weixiu Luo, et al. · Journal of Clinical Oncology · 129
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 122
Incidence of New‐Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
2013 · Kathy H. Fraeman, Beth L. Nordstrom, et al. · International Journal of Hypertension · 61
PDF
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
2019 · Andrea P. Myers, Panagiotis A. Konstantinopoulos, et al. · International Journal of Cancer · 57
Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma
2010 · Uma N. M. Rao, Sandra J. Lee, et al. · American Journal of Clinical Pathology · 57
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
2020 · Karin Ribi, Weixiu Luo, et al. · Breast Cancer Research and Treatment · 36
Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (≥ 75 years old) Patients With Colorectal Cancer: ECOG 1299
2007 · Howard S. Hochster, Weixiu Luo, et al. · Journal of Clinical Oncology · 32
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
2014 · Joyce Liu, William Thomas Barry, et al. · Journal of Clinical Oncology · 26
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
2017 · Joyce F. Liu, William Thomas Barry, et al. · Journal of Clinical Oncology · 14
Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).
2014 · Juerg Bernhard, Weixiu Luo, et al. · Journal of Clinical Oncology · 14
Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter
2008 · Beth L. Nordstrom, Weixiu Luo, et al. · Journal of Managed Care Pharmacy · 14
PDF
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
2019 · on behalf of the SOLE Investigators, Karin Ribi, et al. · British Journal of Cancer · 9
PDF
SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).
2017 · Marco Colleoni, Weixiu Luo, et al. · Journal of Clinical Oncology · 9
Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: Results of a retrospective study of an electronic medical-records database in the United States, 2002–2006
2008 · Weixiu Luo, Beth L. Nordstrom, et al. · Clinical Therapeutics · 9
Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po
2015 · Karin Ribi, Weixiu Luo, et al. · Cancer Research · 8
Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
2019 · Panagiotis A. Konstantinopoulos, Joyce F. Liu, et al. · Journal of Clinical Oncology · 7
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
2020 · Karin Ribi, Weixiu Luo, et al. · British Journal of Cancer · 5
PDF
Works count: 39
Citation count: 3,207
H-index: 16
I10-index: 19
Year
Topic
Type